Neha Patel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Neha Patel has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- David J. Taber
Department of Surgery Medical University of South Carolina Charleston South Carolina USA
4 shared publications Erika Andrade
Department of Surgery Medical University of South Carolina Charleston South Carolina USA
3 shared publicationsFelicia Bartlett
Department of Pharmacy Services Medical University of South Carolina Charleston South Carolina USA
3 shared publicationsNikhil Rao
Department of Surgery Medical University of South Carolina Charleston South Carolina USA
3 shared publications- Shikha Patel
Department of Pharmacy Services Medical University of South Carolina Charleston South Carolina USA
3 shared publications Taylor Sprague
Department of Pharmacy Services Medical University of South Carolina Charleston South Carolina USA
3 shared publications
Latest Publications
- 31 October 2025
- Published by Wiley in Clinical Transplantation
- Vol. 39 (11) , e70363
Improved LCP Tacrolimus Dosing and Monitoring Outcomes With a Genotype‐Based Dosing Algorithm Versus Weight Based Dosing
The aim of this study was to assess the impact of CYP3A5 genotype‐based LCP tacrolimus (tac) versus weight‐based dosing among adult kidney transplant recipients. This was a retrospective longitudinal matched cohort analysis. From February 2021 to June 2023, LCP tac was dosed using standard weight‐based dosing. Starting in June 2023, genotype‐based dosing was used; 148 patients were included (74 in each arm). Baseline characteristics were well balanced between the groups, except for age (control 46 ± 14 vs. 52 ± 14 years, p < 0.01); 32% were females, 36% were African American, 84% were living donors, 40% had DM, and 10% had DGF. At 90‐days post‐txp, the genotype guided cohort had an average of two fewer tacrolimus dose adjustments per patients (4 vs. 6, p < 0.0001), spent longer time in therapeutic range (59% vs. 47%, p = 0.004), and less time in concerning range (9% vs. 18%, p < 0.0001). Acute rejection, de novo donor specific antibodies, and eGFR was similar between the two cohorts. This matched cohort analysis assessing a genotype‐based dosing algorithm demonstrated improved LCP tac dosing efficiency. Patients on average, needed two fewer dose adjustments, spent longer time in therapeutic range and had significantly less time in concerning range.
- 31 October 2025
- Published by Wiley in Clinical Transplantation
- Vol. 39 (11) , e70363
Improved LCP Tacrolimus Dosing and Monitoring Outcomes With a Genotype‐Based Dosing Algorithm Versus Weight Based Dosing
The aim of this study was to assess the impact of CYP3A5 genotype‐based LCP tacrolimus (tac) versus weight‐based dosing among adult kidney transplant recipients. This was a retrospective longitudinal matched cohort analysis. From February 2021 to June 2023, LCP tac was dosed using standard weight‐based dosing. Starting in June 2023, genotype‐based dosing was used; 148 patients were included (74 in each arm). Baseline characteristics were well balanced between the groups, except for age (control 46 ± 14 vs. 52 ± 14 years, p < 0.01); 32% were females, 36% were African American, 84% were living donors, 40% had DM, and 10% had DGF. At 90‐days post‐txp, the genotype guided cohort had an average of two fewer tacrolimus dose adjustments per patients (4 vs. 6, p < 0.0001), spent longer time in therapeutic range (59% vs. 47%, p = 0.004), and less time in concerning range (9% vs. 18%, p < 0.0001). Acute rejection, de novo donor specific antibodies, and eGFR was similar between the two cohorts. This matched cohort analysis assessing a genotype‐based dosing algorithm demonstrated improved LCP tac dosing efficiency. Patients on average, needed two fewer dose adjustments, spent longer time in therapeutic range and had significantly less time in concerning range.
- Open Access
- 1 January 2025
- Published by Wiley in International Journal of Hepatology
- Vol. 2025 (1)
Results of a Randomized Controlled Trial Evaluating the Impact of Conversion to LCP Tacrolimus on Neurologic Toxicities in Liver Transplant Recipients
Background/Aims: Neurotoxicity is commonly seen in liver transplant (LT) patients receiving tacrolimus. We sought to determine the impact of LCP tacrolimus on neurologic toxicity in LT recipients. Methods: This single‐center, semiblinded, parallel group randomized controlled trial compared neurotoxicity burden in LT patients receiving immediate‐release (IR) tacrolimus versus LCP tacrolimus. Thirty LT recipients transplanted between January 2020 and February 2022 were enrolled between 15 and 364 days posttransplant and followed for 6 months postrandomization. The primary endpoint was change from baseline to 6 months in composite Patient Global Impression of Improvement (PGI‐I) score. Select secondary endpoints included change in Fahn–Tolosa–Marin (FTM) Tremor Rating Scale, IMAB‐Q10, SF‐12, and Medical Symptom Validity Test (MSVT) scores. Results: No significant differences were seen in composite PGI scores, though all patients saw improvement in overall PGI scores (IR −5 [−13.5 to −0.25] vs. LCP −4 [−9.5 to −0.5], p = 0.78). Other tests examining neurotoxicities showed no difference between groups but an overall trend toward improvement in symptoms between baseline and end of study. One episode of moderate rejection (rejection activity index [RAI] score of 6) was reported in the LCP group, with no episodes in the IR group ( p = 0.31). No graft loss or mortality occurred in either group. Conclusions: Our study showed LCP tacrolimus had similar rates of neurotoxicity in LT recipients compared to IR without increasing the risk of rejection, graft loss, or mortality; these results suggest LCP tacrolimus can be a safe alternative in LT recipients. Trial Registration: ClinicalTrials.gov identifier: NCT03823768
- 1 January 2025
- Published by Wiley in International Journal of Hepatology
- Vol. 2025 (1)
Open AccessResults of a Randomized Controlled Trial Evaluating the Impact of Conversion to LCP Tacrolimus on Neurologic Toxicities in Liver Transplant Recipients
Background/Aims: Neurotoxicity is commonly seen in liver transplant (LT) patients receiving tacrolimus. We sought to determine the impact of LCP tacrolimus on neurologic toxicity in LT recipients. Methods: This single‐center, semiblinded, parallel group randomized controlled trial compared neurotoxicity burden in LT patients receiving immediate‐release (IR) tacrolimus versus LCP tacrolimus. Thirty LT recipients transplanted between January 2020 and February 2022 were enrolled between 15 and 364 days posttransplant and followed for 6 months postrandomization. The primary endpoint was change from baseline to 6 months in composite Patient Global Impression of Improvement (PGI‐I) score. Select secondary endpoints included change in Fahn–Tolosa–Marin (FTM) Tremor Rating Scale, IMAB‐Q10, SF‐12, and Medical Symptom Validity Test (MSVT) scores. Results: No significant differences were seen in composite PGI scores, though all patients saw improvement in overall PGI scores (IR −5 [−13.5 to −0.25] vs. LCP −4 [−9.5 to −0.5], p = 0.78). Other tests examining neurotoxicities showed no difference between groups but an overall trend toward improvement in symptoms between baseline and end of study. One episode of moderate rejection (rejection activity index [RAI] score of 6) was reported in the LCP group, with no episodes in the IR group ( p = 0.31). No graft loss or mortality occurred in either group. Conclusions: Our study showed LCP tacrolimus had similar rates of neurotoxicity in LT recipients compared to IR without increasing the risk of rejection, graft loss, or mortality; these results suggest LCP tacrolimus can be a safe alternative in LT recipients. Trial Registration: ClinicalTrials.gov identifier: NCT03823768
- 3 October 2023
- Published by Wiley in Clinical Transplantation
- Vol. 37 (12) , e15149
Impact of obesity on the conversion of immediate‐release tacrolimus to extended‐release tacrolimus in kidney transplant recipients
Outcomes analyzing conversion from IR‐tacrolimus (IR) to LCP‐tacrolimus (LCP) in obesity are limited. This was a retrospective longitudinal cohort study of patients converted from IR to LCP from June 2019 to October 2020. Primary outcomes were conversion ratios for weight‐based dose at a steady‐state therapeutic level and identification of appropriate dosing weight. Other outcomes included tacrolimus coefficient of variation (CV), time in therapeutic range (TITR), adverse events, infections, donor specific antibodies (DSAs), and acute rejection. A total of 292 patients were included; 156 and 136 patients with a BMI < 30 and BMI ≥ 30 kg/m2, respectively. Baseline characteristics were similar, except for pancreas transplant, diabetes, and HLA mismatch. IR to LCP conversion ratio ranged from .73 to .79. Mean LCP dose was similar (.08 vs. .07 mg/kg/day for BMI < 30 and BMI ≥ 30 kg/m2, respectively); there was a significant difference in IR and LCP mg/kg dosing at steady state with TBW (.11 mg/kg vs.09 mg/kg and .08 mg/kg vs. .06 mg/kg, respectively). The most appropriate dosing weight was adjusted body weight (AdjBW), consistent across IR and LCP steady‐state doses, and might yield more accurate steady‐state dosing requirements. In multivariable modeling, BMI was a significant predictor of steady state mg/kg dosing at therapeutic goal for total body weight (TBW), but not ideal body weight (IBW) or AdjBW.
- 3 October 2023
- Published by Wiley in Clinical Transplantation
- Vol. 37 (12) , e15149
Impact of obesity on the conversion of immediate‐release tacrolimus to extended‐release tacrolimus in kidney transplant recipients
Outcomes analyzing conversion from IR‐tacrolimus (IR) to LCP‐tacrolimus (LCP) in obesity are limited. This was a retrospective longitudinal cohort study of patients converted from IR to LCP from June 2019 to October 2020. Primary outcomes were conversion ratios for weight‐based dose at a steady‐state therapeutic level and identification of appropriate dosing weight. Other outcomes included tacrolimus coefficient of variation (CV), time in therapeutic range (TITR), adverse events, infections, donor specific antibodies (DSAs), and acute rejection. A total of 292 patients were included; 156 and 136 patients with a BMI < 30 and BMI ≥ 30 kg/m2, respectively. Baseline characteristics were similar, except for pancreas transplant, diabetes, and HLA mismatch. IR to LCP conversion ratio ranged from .73 to .79. Mean LCP dose was similar (.08 vs. .07 mg/kg/day for BMI < 30 and BMI ≥ 30 kg/m2, respectively); there was a significant difference in IR and LCP mg/kg dosing at steady state with TBW (.11 mg/kg vs.09 mg/kg and .08 mg/kg vs. .06 mg/kg, respectively). The most appropriate dosing weight was adjusted body weight (AdjBW), consistent across IR and LCP steady‐state doses, and might yield more accurate steady‐state dosing requirements. In multivariable modeling, BMI was a significant predictor of steady state mg/kg dosing at therapeutic goal for total body weight (TBW), but not ideal body weight (IBW) or AdjBW.
- 27 February 2023
- Published by Wiley in Clinical Transplantation
- Vol. 37 (5) , e14941
Impact of converting adult kidney transplant recipients with high tacrolimus variability from twice daily immediate release tacrolimus to once daily LCP‐Tacrolimus
Background: The influence of converting to once daily, extended‐release LCP‐Tacrolimus (Tac) for those with high tacrolimus variability in kidney transplant recipients (KTRs) is not well‐studied.Methods: Single‐center, retrospective cohort study of adult KTRs converted from Tac immediate release to LCP‐Tac 1‐2 years post‐transplant. Primary measures were Tac variability, using the coefficient of variation (CV) and time in therapeutic range (TTR), as well as clinical outcomes (rejection, infections, graft loss, death).Results: A total of 193 KTRs included with a follow‐up of 3.2 ± .7 years and 1.3 ± .3 years since LCP‐Tac conversion. Mean age was 52 ± 13 years; 70% were African American, 39% were female, 16% living donor and 12% donor after cardiac death (DCD). In the overall cohort, tac CV was 29.5% before conversion, which increased to 33.4% after LCP‐Tac (p = .008). In those with Tac CV >30% (n = 86), conversion to LCP‐Tac reduced variability (40.6% vs. 35.5%; p = .019) and for those with Tac CV >30% and nonadherence or med errors (n = 16), LCP‐Tac conversion substantially reduced Tac CV (43.4% vs. 29.9%; p = .026). TTR significantly improved for those with Tac CV >30% with (52.4% vs. 82.8%; p = .027) or without nonadherence or med errors (64.8% vs. 73.2%; p = .005). CMV, BK, and overall infections were significantly higher prior to LCP‐Tac conversion. In the overall cohort, 3% had rejection before conversion and 2% after (p = NS). At end of follow‐up, graft and patient survival were 94% and 96%, respectively.Conclusions: In those with high Tac CV, conversion to LCP‐Tac is associated with a significant reduction in variability and improvement in TTR, particularly in those with nonadherence or medication errors.
- 27 February 2023
- Published by Wiley in Clinical Transplantation
- Vol. 37 (5) , e14941
Impact of converting adult kidney transplant recipients with high tacrolimus variability from twice daily immediate release tacrolimus to once daily LCP‐Tacrolimus
Background: The influence of converting to once daily, extended‐release LCP‐Tacrolimus (Tac) for those with high tacrolimus variability in kidney transplant recipients (KTRs) is not well‐studied.Methods: Single‐center, retrospective cohort study of adult KTRs converted from Tac immediate release to LCP‐Tac 1‐2 years post‐transplant. Primary measures were Tac variability, using the coefficient of variation (CV) and time in therapeutic range (TTR), as well as clinical outcomes (rejection, infections, graft loss, death).Results: A total of 193 KTRs included with a follow‐up of 3.2 ± .7 years and 1.3 ± .3 years since LCP‐Tac conversion. Mean age was 52 ± 13 years; 70% were African American, 39% were female, 16% living donor and 12% donor after cardiac death (DCD). In the overall cohort, tac CV was 29.5% before conversion, which increased to 33.4% after LCP‐Tac (p = .008). In those with Tac CV >30% (n = 86), conversion to LCP‐Tac reduced variability (40.6% vs. 35.5%; p = .019) and for those with Tac CV >30% and nonadherence or med errors (n = 16), LCP‐Tac conversion substantially reduced Tac CV (43.4% vs. 29.9%; p = .026). TTR significantly improved for those with Tac CV >30% with (52.4% vs. 82.8%; p = .027) or without nonadherence or med errors (64.8% vs. 73.2%; p = .005). CMV, BK, and overall infections were significantly higher prior to LCP‐Tac conversion. In the overall cohort, 3% had rejection before conversion and 2% after (p = NS). At end of follow‐up, graft and patient survival were 94% and 96%, respectively.Conclusions: In those with high Tac CV, conversion to LCP‐Tac is associated with a significant reduction in variability and improvement in TTR, particularly in those with nonadherence or medication errors.
- 23 February 2023
- Published by Wiley in Clinical Transplantation
- Vol. 37 (5) , e14944
Diabetes is a significant and independent predictor for tacrolimus immediate release and LCP‐tacrolimus conversion ratios
Diabetes (DM) is a common comorbidity in transplant patients with known effects on gastrointestinal (GI) motility and absorption; however, DM's impact on immediate release (IR) tacrolimus to LCP‐tacrolimus (LCP) conversion ratios has not been studied. This multivariable analysis of a retrospective longitudinal cohort study included kidney transplant recipients converted from IR to LCP between 2019 and 2020. The primary outcome was IR to LCP conversion ratio based on DM status. Other outcomes included tacrolimus variability, rejection, graft loss, and death. Of the 292 patients included, 172 patients had DM and 120 did not. The IR:LCP conversion ratio was significantly higher with DM (67.5% ± 21.1% no DM vs. 79.8% ± 28.7% in DM; P < .001). In multivariable modeling, DM was the only variable significantly and independently associated with IR:LCP conversion ratios. No difference was observed in rejection rates. Graft (97.5% no DM vs. 92.4% in DM; P = .062) and patient survival (100% no DM vs. 94.8% in DM; P = .011) were lower with DM. The presence of DM significantly increased the IR:LCP conversion ratio by 13%–14%, compared to patients without DM. On multivariable analysis, DM was the only significant predictor of conversion ratios, potentially related to GI motility or absorption differences.
- 23 February 2023
- Published by Wiley in Clinical Transplantation
- Vol. 37 (5) , e14944
Diabetes is a significant and independent predictor for tacrolimus immediate release and LCP‐tacrolimus conversion ratios
Diabetes (DM) is a common comorbidity in transplant patients with known effects on gastrointestinal (GI) motility and absorption; however, DM's impact on immediate release (IR) tacrolimus to LCP‐tacrolimus (LCP) conversion ratios has not been studied. This multivariable analysis of a retrospective longitudinal cohort study included kidney transplant recipients converted from IR to LCP between 2019 and 2020. The primary outcome was IR to LCP conversion ratio based on DM status. Other outcomes included tacrolimus variability, rejection, graft loss, and death. Of the 292 patients included, 172 patients had DM and 120 did not. The IR:LCP conversion ratio was significantly higher with DM (67.5% ± 21.1% no DM vs. 79.8% ± 28.7% in DM; P < .001). In multivariable modeling, DM was the only variable significantly and independently associated with IR:LCP conversion ratios. No difference was observed in rejection rates. Graft (97.5% no DM vs. 92.4% in DM; P = .062) and patient survival (100% no DM vs. 94.8% in DM; P = .011) were lower with DM. The presence of DM significantly increased the IR:LCP conversion ratio by 13%–14%, compared to patients without DM. On multivariable analysis, DM was the only significant predictor of conversion ratios, potentially related to GI motility or absorption differences.
- 17 June 2021
- Published by Elsevier in The American Journal of Surgery
- Vol. 223 (4) , 812-816
The impact of race on metabolic, graft, and patient outcomes after pancreas transplantation
- 17 June 2021
- Published by Elsevier in The American Journal of Surgery
- Vol. 223 (4) , 812-816
The impact of race on metabolic, graft, and patient outcomes after pancreas transplantation